Updated on 29 April 2015
Mr Vivek Sharma, CEO-pharma solutions division, Piramal Enterprise
Singapore: The global CRAMS (Contract Research and Manufacturing Services) segment is becoming intensely competitive. Cost pressures and heightened regulatory intensity pose key challenges to this sector.
In his gripping interview with BioSpectrum's Raj Gunashekar, Mr Vivek Sharma, CEO-pharma solutions division, Piramal Enterprise, shares his exclusive views on the company's organic and inorganic growth plans, trends shaping up the industry, investments in new technologies, R&D cost pressures, and the impact of Mumbai R&D unit shut down last year.
In January 2015, the company acquired US-based specialty pharmaceutical contract manufacturer, Coldstream, an eight-year-old organization with a focus on clinical trial to commercial-scale manufacturing of sterile liquid and lyophilized parenterals and injectables.
Mr Sharma says that the contract manufacturing market for sterile injectables is expected to grow at an extremely fast rate.
The CRAMS sector worldwide is highly fragmented, and is estimated to be growing at a CAGR of 7 percent.
He reveals that the company has significantly invested in ADC (Antibody Drug Conjugate), a new technology.